Still to be signed off on is contentious language governing the sharing of technology for pandemic-related products such as drugs, vaccines and therapeutics.
Developing countries have pushed for strong language that will ensure they are able to scale up production in their own regions, rather than waiting in line for critical technologies.
But developed countries, including members of the European Union, have insisted throughout that any tech transfer from pharma companies must be on “voluntary and mutually agreed terms.”
Under the latest proposed fix, still subject to final confirmation, the sharing of technology should be “willingly undertaken and on mutually agreed terms.”
The deal is due to go to the WHO’s annual assembly for final approval next month.
